U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program

Published:2020-08-19 Issue:1 Volume:27 Page:11-14
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

de Claro R. Angelo,Gao Jennifer J.^ORCID,Kim Tamy,Kluetz Paul G.,Theoret Marc R.,Beaver Julia A.,Pazdur Richard

Funder

not applicable

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals;JAMA Network Open;2024-05-01

2. The US Food and Drug Administration Dual Mandate for Rapid Drug Review and Equity;JAMA Network Open;2024-05-01

3. US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019;JAMA Network Open;2023-06-26

4. FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC;Clinical Cancer Research;2023-03-23

5. Modeling Approaches to Reimagine Stability (MARS) for Enabling Earlier Access to Critical Drugs for Patients with Unmet Medical Needs;AAPS PharmSciTech;2023-01-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP